



MannKind to Present at the 29th Annual Canaccord Adams Global Growth Conference

08/06/09

MannKind to Present at the 29th Annual Canaccord Adams Global Growth Conference

VALENCIA, Calif., Aug 06, 2009 (BUSINESS WIRE) -- MannKind Corporation (Nasdaq:MNKD), focused on discovering, developing and commercializing treatments for diabetes and cancer, announced today that it will present at the 29th Annual Canaccord Adams Global Growth Conference on Wednesday, August 12, 2009 at 1:00 PM (EDT) at the InterContinental Hotel in Boston, Massachusetts.

Interested parties can access a link to the live webcast of the presentation from the News & Events section of the Company's website at <http://www.mannkindcorp.com>. Replays of the presentations will be available for 14 days.

About MannKind Corporation

MannKind Corporation (Nasdaq:MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. Its pipeline includes AFRESA[®], MKC253, MKC1106-PP, and MKC1106-MT. MannKind has submitted an NDA to the FDA requesting approval of AFRESA for the treatment of adults with type 1 or type 2 diabetes for the control of hyperglycemia. Its other programs are currently in Phase 1 clinical trials. MannKind maintains a website at <http://www.mannkindcorp.com> to which MannKind regularly posts copies of its press releases as well as additional information about MannKind. Interested persons can subscribe on the MannKind website to e-mail alerts that are sent automatically when MannKind issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the website.

SOURCE: MannKind Corporation

MannKind Corporation

Matthew J. Pfeffer

Corporate Vice President and
Chief Financial Officer

661-775-5300

mpfeffer@mannkindcorp.com